![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Lilly Research Laboratories, Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana
Traditionally, the Michaelis-Menten equation has been used to determine kinetic parameters for in vitro glucuronidation assays. Recently, estradiol-3-glucuronide formation was shown to exhibit non-Michaelis-Menten kinetics consistent with autoactivation. A concern with the observation of nontraditional kinetics is that they may result as an artifact of the incubation conditions. To examine this concern, the formation of estradiol-3-glucuronide was investigated using human liver microsomes prepared by two different methods, a range of assay conditions, and activation by alamethecin, sonication, or Brij 58 (polyoxyethylene monocetyl ether). Interestingly, holding the other assay components constant, estradiol-3-glucuronide formation was up to 2.5-fold greater using microsomes prepared in phosphate buffer compared with those prepared in sucrose. Incubations activated by alamethecin consistently exhibited the highest rates of estradiol glucuronidation versus the other activators. Furthermore, estradiol-3-glucuronidation exhibited autoactivation kinetics in all of the conditions investigated (n = 1.2–1.7). Nontraditional kinetics were also observed when other UGT1A1 substrates such as ethinylestradiol, buprenorphine, and anthraflavic acid were studied with both human liver microsomes and recombinant UGT1A1. Naphthol, propofol, morphine, and androstanediol were used as probe UGT substrates selective for UGT1A6, UGT1A9, UGT2B7, and UGT2B15, respectively. Of these substrates, only androstanediol exhibited nontraditional kinetics using human liver microsomes. In conclusion, the Hill and/or Michaelis-Menten equations should be used to fit kinetic data to obtain an accurate assessment of in vitro glucuronidation.
This article has been cited by other articles:
|
|
 |
|
  R. Fujiwara, M. Nakajima, H. Yamanaka, and T. Yokoi Key Amino Acid Residues Responsible for the Differences in Substrate Specificity of Human UDP-Glucuronosyltransferase (UGT)1A9 and UGT1A8 Drug Metab. Dispos., January 1, 2009; 37(1): 41 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Kilford, R. Stringer, B. Sohal, J. B. Houston, and A. Galetin Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes Drug Metab. Dispos., January 1, 2009; 37(1): 82 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ohno, K. Kawana, and S. Nakajin Contribution of UDP-Glucuronosyltransferase 1A1 and 1A8 to Morphine-6-Glucuronidation and Its Kinetic Properties Drug Metab. Dispos., April 1, 2008; 36(4): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Zhu, D. Bush, G. A. Doss, S. Vincent, R. B. Franklin, and S. Xu Characterization of 1'-Hydroxymidazolam Glucuronidation in Human Liver Microsomes Drug Metab. Dispos., February 1, 2008; 36(2): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Product Inhibition of UDP-Glucuronosyltransferase (UGT) Enzymes by UDP Obfuscates the Inhibitory Effects of UGT Substrates Drug Metab. Dispos., February 1, 2008; 36(2): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Omura, T. Nakazawa, T. Sato, T. Iwanaga, and O. Nagata Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor Drug Metab. Dispos., December 1, 2007; 35(12): 2143 - 2148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhang, D. Zhang, D. Cui, J. Gambardella, L. Ma, A. Barros, L. Wang, Y. Fu, S. Rahematpura, J. Nielsen, et al. Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism Drug Metab. Dispos., December 1, 2007; 35(12): 2270 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Kuester and I. G. Sipes Prediction of Metabolic Clearance of Bisphenol A (4,4 '-Dihydroxy-2,2-diphenylpropane) using Cryopreserved Human Hepatocytes Drug Metab. Dispos., October 1, 2007; 35(10): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wong, V. Tong, K. W. Riggs, D. W. Rurak, F. S. Abbott, and S. Kumar Kinetics of Valproic Acid Glucuronidation: Evidence for in Vivo Autoactivation Drug Metab. Dispos., August 1, 2007; 35(8): 1380 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fujiwara, M. Nakajima, H. Yamanaka, A. Nakamura, M. Katoh, S.-i. Ikushiro, T. Sakaki, and T. Yokoi Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A Isoforms Drug Metab. Dispos., May 1, 2007; 35(5): 747 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Wen, M. N. Tallman, S. Y. Ali, and P. C. Smith UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics Drug Metab. Dispos., March 1, 2007; 35(3): 371 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Zaya, R. N. Hines, and J. C. Stevens Epirubicin Glucuronidation and UGT2B7 Developmental Expression Drug Metab. Dispos., December 1, 2006; 34(12): 2097 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chouinard, M. Tessier, G. Vernouillet, S. Gauthier, F. Labrie, O. Barbier, and A. Belanger Inactivation of the Pure Antiestrogen Fulvestrant and Other Synthetic Estrogen Molecules by UDP-Glucuronosyltransferase 1A Enzymes Expressed in Breast Tissue Mol. Pharmacol., March 1, 2006; 69(3): 908 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Engtrakul, R. S. Foti, T. J. Strelevitz, and M. B. Fisher ALTERED AZT (3'-AZIDO-3'-DEOXYTHYMIDINE) GLUCURONIDATION KINETICS IN LIVER MICROSOMES AS AN EXPLANATION FOR UNDERPREDICTION OF IN VIVO CLEARANCE: COMPARISON TO HEPATOCYTES AND EFFECT OF INCUBATION ENVIRONMENT Drug Metab. Dispos., November 1, 2005; 33(11): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Luukkanen, J. Taskinen, M. Kurkela, R. Kostiainen, J. Hirvonen, and M. Finel KINETIC CHARACTERIZATION OF THE 1A SUBFAMILY OF RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES Drug Metab. Dispos., July 1, 2005; 33(7): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Marco, M. D'Antoni, S. Attaccalite, P. Carotenuto, and R. Laufer DETERMINATION OF DRUG GLUCURONIDATION AND UDP-GLUCURONOSYLTRANSFERASE SELECTIVITY USING A 96-WELL RADIOMETRIC ASSAY Drug Metab. Dispos., June 1, 2005; 33(6): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takeda, Y. Ishii, M. Iwanaga, P. I. Mackenzie, K. Nagata, Y. Yamazoe, K. Oguri, and H. Yamada Modulation of UDP-Glucuronosyltransferase Function by Cytochrome P450: Evidence for the Alteration of UGT2B7-Catalyzed Glucuronidation of Morphine by CYP3A4 Mol. Pharmacol., March 1, 2005; 67(3): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Williams, R. Hyland, B. C. Jones, D. A. Smith, S. Hurst, T. C. Goosen, V. Peterkin, J. R. Koup, and S. E. Ball DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS Drug Metab. Dispos., November 1, 2004; 32(11): 1201 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Uchaipichat, P. I. Mackenzie, X.-H. Guo, D. Gardner-Stephen, A. Galetin, J. B. Houston, and J. O. Miners HUMAN UDP-GLUCURONOSYLTRANSFERASES: ISOFORM SELECTIVITY AND KINETICS OF 4-METHYLUMBELLIFERONE AND 1-NAPHTHOL GLUCURONIDATION, EFFECTS OF ORGANIC SOLVENTS, AND INHIBITION BY DICLOFENAC AND PROBENECID Drug Metab. Dispos., April 1, 2004; 32(4): 413 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Soars, D. M. Petullo, J. A. Eckstein, S. C. Kasper, and S. A. Wrighton AN ASSESSMENT OF UDP-GLUCURONOSYLTRANSFERASE INDUCTION USING PRIMARY HUMAN HEPATOCYTES Drug Metab. Dispos., January 1, 2004; 32(1): 140 - 148. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
